Moderna Reports the P-III Study Data of mRNA-1083 Vaccine Against Influenza and COVID-19
Shots:
- The P-III study assesses the safety, reactogenicity & immunogenicity of mRNA-1083 (combination of mRNA-1010 influenza & mRNA-1283 next-gen. COVID-19 vaccine) vs Fluzone HD influenza vaccine & Spikevax COVID-19 vaccine (≥65yrs. age group) as well as Fluarix influenza vaccine & Spikevax (50 to 64yrs. age group); each arm has ~4000 patients
- The vaccine showed overall GMRs for influenza strains of 1.155 (A/H1N1), 1.063 (A/H3N2) & 1.118 (B/Victoria) as well as 1.641 for Omicron XBB.1.5 variant among ≥65yrs. age group
- Furthermore, the GMRs for influenza strains of 1.414 (A/H1N1), 1.380 (A/H3N2) & 1.216 (B/Victoria) as well as 1.308 for Omicron XBB.1.5 variant were observed in 50 to 64yrs. age group. Results will be highlighted at future conferences
Ref: Moderna | Image: Moderna
Related News:- Moderna Collaborates with OpenAI to Advance mRNA Medicine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
